Observational studyRheumatology international2021
A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis.
Observational study in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2025Guideline
- Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2023Guideline
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
- Review
- Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series.Internal medicine (Tokyo, Japan) · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Successful treatment of Kimura disease with Mycophenolate Mofetil: a report of two cases and review of the literature.Rheumatology international · 2025Review
- Eosinophilic Granulomatous Polyangiitis with Autoimmune Hemolytic Anemia: A Case Report and Review of the Literature.Journal of asthma and allergy · 2025Article
- Eosinophilic granulomatosis with polyangiitis; a distinctive presentation with myocarditis and autoimmune haemolytic anaemia: case report.Frontiers in cardiovascular medicine · 2024Article
- Eosinophilic granulomatosis with polyangiitis: case report and literature review.Breathe (Sheffield, England) · 2022Review
- [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].Zeitschrift fur Rheumatologie · 2022Review
- Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of ANCA-associated vasculitis (AAV). Clinical trials demonstrating the efficacy of mycophenolate mofetil (MMF) for remission induction in AAV excluded patients with EGPA. Despite this, MMF is commonly used in these patients. The objective of this study was to evaluate, for the first time, the effectiveness and tolerance of MMF in EGPA remission induction. A retrospective, two-center, real-world study was conducted in patients with EGPA who received MMF in addition to prednisolone for newly diagnosed or relapsing disease between 2009 and 2019. Baseline, 3-, 6- and 12-month outcome data were extracted from electronic health records. The primary outcome was disease remission, defined as a Birmingham Vasculitis Activity Score of 0 at 6 months. Secondary outcomes included disease relapse, median prednisolone dose at 12 months and drug tolerance. In total, 15 patients (73% male, median age 57) with EGPA (11 newly diagnosed/4 relapsing) were identified. At 6 months, 67% had achieved disease remission. At 12 months, this was maintained (66.7%) and 4 patients had relapsed. All but one patient remained on MMF at study completion and all patients tolerated MMF. Our real-world data suggest that MMF is an effective and well-tolerated agent for achieving disease remission in EGPA. A future randomized controlled trial of MMF in this neglected orphan disease is now warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.